Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05323929
Other study ID # 2021-0634
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date December 31, 2027

Study information

Verified date April 2022
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Yuqi Wang, Doctor
Phone +86-15267019821
Email wyq@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by ESD, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.


Description:

This project intends to compare the scar size of ESD for early gastric cancer with different peeling depths, explore the relationship between ESD peeling depth, scar formation and gastric function, and clarify the differential impact of different peeling depths on the prognosis of patients. We plan to provide evidence for guidelines of early gastric cancer ESD treatment based on the related data. In further, the project show insight into a more effective clinical technique which profit patients better prognosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients older than 18 years old and younger than 75 years old. - Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter <3cm; or early gastric cancer (T1a stage), undifferentiated and No ulcer, lesion diameter <2cm. - Pathological diagnosis of gastric cancer. - No further treatment is required. - Patients diagnosed for the first time without other serious gastrointestinal diseases. Exclusion Criteria: - Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment. - Advanced gastric cancer; or undifferentiated gastric cancer lesions > 2 cm in diameter; or differentiated gastric cancer with ulcer lesions > 3 cm in diameter. - Coagulation disorders. - Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment. - Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment. - Patients with distant metastasis. - Patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ. - The patient himself requests to withdraw from the trial. - The researcher believes that the patient is not suitable to participate in this study.

Study Design


Intervention

Procedure:
ESD
Endoscopic Submucosal Dissection for early gastric cancer

Locations

Country Name City State
China Second affiliated hospital, school of medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

References & Publications (6)

Chung IK, Lee JH, Lee SH, Kim SJ, Cho JY, Cho WY, Hwangbo Y, Keum BR, Park JJ, Chun HJ, Kim HJ, Kim JJ, Ji SR, Seol SY. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc. 2009 Jun;69(7):1228-35. doi: 10.1016/j.gie.2008.09.027. Epub 2009 Feb 27. — View Citation

Ono H, Yao K, Fujishiro M, Oda I, Uedo N, Nimura S, Yahagi N, Iishi H, Oka M, Ajioka Y, Fujimoto K. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc. 2021 Jan;33(1):4-20. doi: 10.1111/den.13883. Epub 2020 Dec 9. Review. — View Citation

Russo AE, Strong VE. Gastric Cancer Etiology and Management in Asia and the West. Annu Rev Med. 2019 Jan 27;70:353-367. doi: 10.1146/annurev-med-081117-043436. Epub 2018 Oct 24. Review. — View Citation

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. — View Citation

Toyonaga T, Man-i M, East JE, Nishino E, Ono W, Hirooka T, Ueda C, Iwata Y, Sugiyama T, Dozaiku T, Hirooka T, Fujita T, Inokuchi H, Azuma T. 1,635 Endoscopic submucosal dissection cases in the esophagus, stomach, and colorectum: complication rates and long-term outcomes. Surg Endosc. 2013 Mar;27(3):1000-8. doi: 10.1007/s00464-012-2555-2. Epub 2012 Oct 6. — View Citation

Tsukuma H, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut. 2000 Nov;47(5):618-21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary scar area the scar area after ESD for 1 year 1 year
See also
  Status Clinical Trial Phase
Terminated NCT04977401 - EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection N/A
Not yet recruiting NCT04083573 - Comparison of Diagnostic Performance of Medical Monitor and Medical Augmented Reality Glasses in Endoscopy: Observation Study
Completed NCT02504164 - Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection N/A
Recruiting NCT01774266 - Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer N/A
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Completed NCT01921283 - Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring N/A
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Recruiting NCT03837301 - Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) Phase 2
Recruiting NCT05269056 - Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
Not yet recruiting NCT03632746 - Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
Completed NCT01938326 - Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG) N/A
Recruiting NCT04602689 - Fibrin Glue After ESD for High Risk Patients of Bleeding N/A
Recruiting NCT05291728 - Screening for Early Gastric Cancer in Shaanxi Province
Not yet recruiting NCT06152783 - Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
Completed NCT02189226 - Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection N/A
Completed NCT04602299 - Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors N/A
Completed NCT02562976 - OLGA Stage is More Appropriate in Predicting Early Gastric Cancer N/A
Recruiting NCT01132469 - Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer N/A
Completed NCT03136354 - Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection Against Laparoscopic Assisted Gastrectomy for Treatment of Early Gastric Cancer N/A
Completed NCT02216110 - Endoscopic Submucosal Dissection Versus Gastrectomy N/A